Drugs / recombinant human tissue plasminogen activator
recombinant human tissue plasminogen activator
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy2 trials | ||||||
| Phase 4 | NCT01429350 Comparator | May 2012 → Oct 2016 | ischemic stroke | Penumbra Inc. | Completed | No outcome recorded |
| — | NCT01657461 Comparator | Dec 2012 → Jan 2015 | ischemic stroke | Medtronic Neurovascular Clinical Affairs | Completed | No outcome recorded |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | recombinant human tissue plasminogen activator | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01657461 ↗ |
| Known as | recombinant tissue plasminogen activator, Alteplase | “recombinant tissue plasminogen activator, Alteplase” NCT01429350 ↗ |
| Known as | recombinant tissue-type plasminogen activator | “IV r-tPA (recombinant tissue-type plasminogen activator)” PMID 28596447 ↗ Jun 2017 |
| Known as | rtPA | “intravenous (IV) recombinant human tissue plasminogen activator (rtPA)” NCT01429350 ↗2“Intravenous (IV) recombinant human tissue plasminogen activator (rtPA)” NCT01657461 ↗ “IV r-tPA (recombinant tissue-type plasminogen activator)” PMID 28596447 ↗ Jun 2017 |
| Modality | Protein / enzyme biologic | “recombinant human tissue plasminogen activator (rtPA)” NCT01429350 ↗ |
| Route | Intravenous | “IV infusion of rtPA at 0.9mg/kg to a maximum of 90mg” NCT01429350 ↗ |